content: SECURITIES AND EXCHANGE COMMISSION
  
                               Washington, D.C. 20549
  
                                      FORM 8-K
  
                                   CURRENT REPORT
  
                       Pursuant to Section 13 or 15(d) of the
                           Securities Exchange Act of 1934
  
         Date of Report (Date of earliest event reported): November 24, 1999
  
                                 IMMUNOMEDICS, INC.
               (Exact name of registrant as specified in its charter)
  
  
             Delaware                   0-12104                61-1009366
    (State or Other Jurisdiction      (Commission             (IRS Employer
         of Incorporation)            File Number)          Identification No.)
  
  
  
            300 American Road, Morris Plains, New Jersey     07950
              (Address of principal executive offices)     (Zip Code)
  
         Registrant's telephone number, including area code: (973) 605-8200
  
            (Former name or former address, if changed since last report)
  
  <PAGE>
  
  Item 5.  Other Events
  
           On November 24, 1999,  the  registrant  entered into an agreement  with
  HFTP  Investment  LLC (the  "Investor")  relating to shares of the  registrant's
  Series F Convertible  Preferred Stock (the "Preferred Shares") currently held by
  the  Investor.  Pursuant to the  agreement,  (a) the  registrant  will honor the
  Investor's  request to convert 105 Preferred  Shares into 924,614  shares of the
  registrant's  common stock, and (b) the registrant will have the right to redeem
  up to  the  balance  of  the  Investor's  Preferred  Shares  (consisting  of 445
  Preferred  Shares) at any time on or before  December 15, 1999,  at a redemption
  price  that  varies  from 105% to 109% of par (which is  $10,000  per  Preferred
  Share),  depending  upon when during the period  through  December  15, 1999 the
  registrant  redeems such shares. The registrant is under no obligation to redeem
  such shares either before or after December 15, 1999. However,  the Investor has
  agreed  that it will not convert any  additional  Preferred  Shares on or before
  December  15,  1999,  and  will  not  increase  its net  short  position  in the
  registrant's common stock on or before that date.
  
           The registrant provides no assurance as to whether such redemption will
  be effected.  The registrant is seeking to conclude similar  agreements with the
  other owners of the Preferred Shares and is pursuing  negotiations to obtain the
  financing  necessary  to effect  the  redemption  of its  Preferred  Shares.  No
  assurances  can be given  that  the  registrant  will  enter  into  satisfactory
  arrangements,  or any  arrangements  at all,  with such other owners or with any
  financing source.
  
  
  <PAGE>
  
                                     SIGNATURES
  
           Pursuant to the  requirements  of the Securities  Exchange Act of 1934,
  the  Registrant  has duly  caused  this report to be signed on its behalf by the
  undersigned thereunto duly authorized.
  
  
  
                                                                IMMUNOMEDICS, INC.
  
  
                                                           By:/s/ David Goldenberg
                                                              --------------------
                                                             David Goldenberg
                                                             Chairman of the Board
  
  
  Date:  November 24, 1999
  
  
  <PAGE>
metadata_documents: [{"type": "8-K", "sequence": "1", "description": "8-K", "secsgml_size_bytes": 3425}]
metadata_filer: {"company-data": {"conformed-name": "IMMUNOMEDICS INC", "cik": "0000722830", "assigned-sic": "2835", "irs-number": "611009366", "state-of-incorporation": "DE", "fiscal-year-end": "0630"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-12104", "film-number": "99764598"}, "business-address": {"street1": "300 AMERICAN RD", "city": "MORRIS PLAINS", "state": "NJ", "zip": "07950", "phone": "9736058200"}, "mail-address": {"street1": "300 AMERICAN ROAD", "city": "MORRIS PLAINS", "state": "NJ", "zip": "07950"}}
text: SECURITIES AND EXCHANGE COMMISSION
  
                               Washington, D.C. 20549
  
                                      FORM 8-K
  
                                   CURRENT REPORT
  
                       Pursuant to Section 13 or 15(d) of the
                           Securities Exchange Act of 1934
  
         Date of Report (Date of earliest event reported): November 24, 1999
  
                                 IMMUNOMEDICS, INC.
               (Exact name of registrant as specified in its charter)
  
             Delaware                   0-12104                61-1009366
    (State or Other Jurisdiction      (Commission             (IRS Employer
         of Incorporation)            File Number)          Identification No.)
  
            300 American Road, Morris Plains, New Jersey     07950
              (Address of principal executive offices)     (Zip Code)
  
         Registrant's telephone number, including area code: (973) 605-8200
  
            (Former name or former address, if changed since last report)
  Item 5.  Other Events
  
           On November 24, 1999,  the  registrant  entered into an agreement  with
  HFTP  Investment  LLC (the  "Investor")  relating to shares of the  registrant's
  Series F Convertible  Preferred Stock (the "Preferred Shares") currently held by
  the  Investor.  Pursuant to the  agreement,  (a) the  registrant  will honor the
  Investor's  request to convert 105 Preferred  Shares into 924,614  shares of the
  registrant's  common stock, and (b) the registrant will have the right to redeem
  up to  the  balance  of  the  Investor's  Preferred  Shares  (consisting  of 445
  Preferred  Shares) at any time on or before  December 15, 1999,  at a redemption
  price  that  varies  from 105% to 109% of par (which is  $10,000  per  Preferred
  Share),  depending  upon when during the period  through  December  15, 1999 the
  registrant  redeems such shares. The registrant is under no obligation to redeem
  such shares either before or after December 15, 1999. However,  the Investor has
  agreed  that it will not convert any  additional  Preferred  Shares on or before
  December  15,  1999,  and  will  not  increase  its net  short  position  in the
  registrant's common stock on or before that date.
  
           The registrant provides no assurance as to whether such redemption will
  be effected.  The registrant is seeking to conclude similar  agreements with the
  other owners of the Preferred Shares and is pursuing  negotiations to obtain the
  financing  necessary  to effect  the  redemption  of its  Preferred  Shares.  No
  assurances  can be given  that  the  registrant  will  enter  into  satisfactory
  arrangements,  or any  arrangements  at all,  with such other owners or with any
  financing source.
  SIGNATURES
  
           Pursuant to the  requirements  of the Securities  Exchange Act of 1934,
  the  Registrant  has duly  caused  this report to be signed on its behalf by the
  undersigned thereunto duly authorized.
  
                                                                IMMUNOMEDICS, INC.
  
                                                           By:/s/ David Goldenberg
                                                              --------------------
                                                             David Goldenberg
                                                             Chairman of the Board
  
  Date:  November 24, 1999